CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 230 enrolled
Drug / intervention
ARQ-252 cream 0.3% +2 moredrug
Likely dose
ARQ-252 cream 0.1% and 0.3%AI-extracted
Key inclusion· 5
  • ✓Age ≥18 years at time of consent
  • ✓Clinical diagnosis of chronic hand eczema persistent for >3 months, or recurrent ≥2 times in last 12 months, generally stable for 6 weeks
  • ✓Hand eczema involving ≥0.3% body surface area total on both hands combined
  • ✓Negative serum pregnancy test at Screening and negative urine pregnancy test at Baseline for females of childbearing potential
Key exclusion· 7
  • ✕Concurrent skin diseases on the hands that could confound the study (e.g., tinea manuum)
  • ✕Any presence or history of psoriasis
  • ✕History of positive patch test with continued exposure to allergen; must have undergone diagnostic patch testing within 3 years prior to Baseline
  • ✕Unable to discontinue systemic and/or topical therapies for chronic hand eczema prior to Baseline and during the study

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04378569
NCT04378569Phase 2Completed
CompareCT.gov

A Phase 1/2b, Multiple Dose and 12-Week, Parallel Group, Double Blind, Dose Ranging, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.1% and ARQ-252 Cream 0.3% in Subjects With Chronic Hand Eczema

Arcutis Biotherapeutics, Inc.·interventional·Posted May 7, 2020·Updated Apr 5, 2024

In Brief

A Phase 2 clinical trial evaluating ARQ-252 cream 0.3%, ARQ-252 cream 0.1%, and 1 other intervention for Chronic Hand Eczema. Completed, enrolled 230 participants across 37 sites in 3 countries.

Detailed Summary

This study will assess the safety and efficacy of ARQ-252 cream in subjects with chronic hand eczema

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hand Eczema
CountriesAustralia, Canada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMay 7, 2020
Enrollment StartApr 20, 2020
Primary CompletionFeb 24, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.2 years ago

Interventions

ARQ-252 cream 0.3%drug

ARQ-252 cream 0.3%

ARQ-252 cream 0.1%drug

ARQ-252 cream 0.1%

ARQ-252 Vehicle Creamdrug

ARQ-252 Vehicle Cream